Open Orphan (which will be rebranded hVIVO starting 26 October) is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). It has reported in the H1FY22 results revenues of
16 Sep 2022
Open Orphan: Booming orders show market leadership
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Open Orphan: Booming orders show market leadership
hVIVO plc (HVO:LON) | 28.6 0 0.4% | Mkt Cap: 194.6m
- Published:
16 Sep 2022 -
Author:
Daniel Appiah -
Pages:
6
Open Orphan (which will be rebranded hVIVO starting 26 October) is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). It has reported in the H1FY22 results revenues of